Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26276366
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Gastric+Cancer
2016 ; 19
(1
): 3-14
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
The standard diagnosis, treatment, and follow-up of gastrointestinal stromal
tumors based on guidelines
#MMPMID26276366
Nishida T
; Blay JY
; Hirota S
; Kitagawa Y
; Kang YK
Gastric Cancer
2016[Jan]; 19
(1
): 3-14
PMID26276366
show ga
Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they
are the commonest sarcoma in the gastrointestinal tract. Molecularly targeted
therapy, such as imatinib therapy, has revolutionized the treatment of advanced
GIST and facilitates scientific research on GIST. Nevertheless, surgery remains a
mainstay of treatment to obtain a permanent cure for GIST even in the era of
targeted therapy. Many GIST guidelines have been published to guide the diagnosis
and treatment of the disease. We review current versions of GIST guidelines
published by the National Comprehensive Cancer Network, by the European Society
for Medical Oncology, and in Japan. All clinical practice guidelines for GIST
include recommendations based on evidence as well as on expert consensus. Most of
the content is very similar, as represented by the following examples: GIST is a
heterogeneous disease that may have mutations in KIT, PDGFRA, HRAS, NRAS, BRAF,
NF1, or the succinate dehydrogenase complex, and these subsets of tumors have
several distinctive features. Although there are some minor differences among the
guidelines--for example, in the dose of imatinib recommended for exon 9-mutated
GIST or the efficacy of antigen retrieval via immunohistochemistry--their common
objectives regarding diagnosis and treatment are not only to improve the
diagnosis of GIST and the prognosis of patients but also to control medical
costs. This review describes the current standard diagnosis, treatment, and
follow-up of GISTs based on the recommendations of several guidelines and expert
consensus.